Literature DB >> 26904200

Distribution of innate efflux-mediated aminoglycoside resistance among different Achromobacter species.

J Bador1, C Neuwirth1, P Liszczynski1, M-C Mézier1, M Chrétiennot1, E Grenot1, A Chapuis1, C de Curraize1, L Amoureux1.   

Abstract

Achromobacter spp. are emerging respiratory pathogens in cystic fibrosis patients. Since 2013 the genus Achromobacter includes 15 species for which innate antibiotic resistance is unknown. Previously the AxyXY-OprZ efflux system has been described to confer aminoglycoside (AG) resistance in A. xylosoxidans. Nevertheless, some Achromobacter spp. strains are susceptible to AG. This study including 49 Achromobacter isolates reveals that AG resistance is correlated with different Achromobacter spp. It is noteworthy that the axyXY-oprZ operon is detected only in AG-resistant species, including the most frequently encountered in cystic fibrosis patients: A. xylosoxidans, A. ruhlandii, A. dolens and A. insuavis.

Entities:  

Keywords:  Achromobacter; AxyXY-OprZ; aminoglycoside resistance; cystic fibrosis; nrdA; selection pressure

Year:  2015        PMID: 26904200      PMCID: PMC4726742          DOI: 10.1016/j.nmni.2015.11.013

Source DB:  PubMed          Journal:  New Microbes New Infect        ISSN: 2052-2975


Achromobacter spp. are nonfermenting Gram-negative bacilli considered as emerging pathogens in cystic fibrosis (CF) patients [1], [2]. Since the description of the type species, A. xylosoxidans [3], 14 other species have been ranked into the genus Achromobacter: A. piechaudii and A. ruhlandii [4], A. denitrificans [5], A. spanius and A. insolitus [6], A. marplatensis [7], A. animicus, A. mucicolens, A. pulmonis and A. spiritinus [8], A. insuavis, A. aegrifaciens, A. anxifer and A. dolens [9], and 6 other genogroups. These 21 species and genogroups can be distinguished by the multilocus sequence typing (MLST) scheme proposed by Spilker et al. [10]. The study demonstrated that sequencing a 765 bp internal fragment of the only nrdA gene is sufficient for correct identification [11]. Because of the actual difficulty in performing accurate species identification, most isolates are still referred by default as A. xylosoxidans, preventing the evaluation of the real epidemiology and clinical impact of each species. Moreover, the data about the mechanisms of innate antibiotic resistance are scarce [12], [13]. The AxyXY-OprZ RND efflux system confers resistance to aminoglycosides (AG) in A. xylosoxidans AXX-A since reclassified as A. insuavis (accession number AFRQ01000000). Nevertheless, AG, which take an important part in CF antimicrobial therapy, remain active against some isolates of Achromobacter spp. [14], [15]. We sought to describe the distribution of AG-resistant isolates among the different species of the genus Achromobacter and to search for the axyXY-oprZ efflux operon in AG-resistant and -susceptible isolates to assess if AG resistance is correlated with the presence of the operon. Forty-nine Achromobacter isolates harbouring various AG resistance patterns were included in this study: 21 from CF patients' sputum, 20 from non-CF clinical samples and eight from environmental samples (Table 1). Most of them (n = 35) were collected in our laboratory; nine collection strains were purchased from the Institut Pasteur, France, including six type strains, and five were kindly provided by J. J. LiPuma (Department of Pediatrics and Communicable Diseases, University of Michigan Medical School). Isolates were identified at the genus level either by using the conventional biochemical method API 20NE (bioMérieux) or by sequencing the 16S rRNA gene. The identification to the species level was performed by sequencing the 765 bp internal nrdA fragment followed by Achromobacter PubMLST database query (http://pubmlst.org/achromobacter/). Minimal inhibitory concentrations (MICs) of tobramycin, amikacin, gentamicin and netilmicin were measured by the Etest method (bioMérieux). Mueller-Hinton agar plates were inoculated by swabbing from a 0.5 McFarland turbidity bacterial suspension, and MICs were recorded after overnight incubation at 37°C by two persons independently. The phenotype “AG-susceptible” (AG-S) was attributed to isolates susceptible to all AG and the phenotype “AG-resistant” (AG-R) to the other by using the European Committee on Antimicrobial Susceptibility Testing clinical breakpoints for Pseudomonas spp. (http://www.eucast.org/clinical_breakpoints/; version 5.0). Detection of the axyXY-oprZ operon was performed by 2 PCRs targeting the genes (a) axyY, encoding the RND transporter, and (b) oprZ, encoding the outer membrane factor. PCRs were carried out in reaction mixtures containing dNTP (0.2 mM), forward and reverse primers (0.25 μM each), Taq polymerase (Fermentas) (2.5 U) with the supplied buffer, MgCl2 (1.5 mM), dimethyl sulfoxide (5% volume) and template DNA (1 μL), adjusted with water to a final volume of 50 μL. The cycling parameters were 94°C for 10 minutes, 30 cycles of 94°C for 90 seconds, annealing primers temperature for 90 sections, 72°C for 60 seconds, and 72°C for 10 minutes. The results are summarized in Table 1.
Table 1

Achromobacter isolates and main results

nrdA identificationIsolateOriginMIC (mg/L)
AG S/RPCR axyYPCR oprZ
TOBAMKGENNET
A. aegrifaciensACH-CF-D59CF sputuma>256>256>256>256R++
A. aegrifaciensACH-CF-802CF sputuma64481632R++
A. aegrifaciensACH-ENV-2Hospital hand-washing sinka12838R++
A. aegrifaciensACH-CF-766CF sputuma192481264R++
A. animicusACH-CF-864CF sputuma1.5411S
A. animicusACH-NCF-33Cathetera1.5622S
A. animicusACH-CF-D63CF sputuma1.541.51S
A. animicusACH-CF-D64CF sputuma2821.5S
A. animicusACH-CF-D65CF sputuma131.51.5S
A. animicusACH-CF-711CF sputuma241.51.5S
A. denitrificansCIP-77.15TSoil322566464R++
A. dolensAU18822CF sputum>25664>25612R++
A. dolensAU20310CF sputum>256>256>256128R++
A. genogroup 12ACH-ENV-3Dialysis watera33288R++
Novel speciesACH-CF-583CF sputuma24>25696>256R++
A. insolitusCIP-108202TLeg wound2563248>256R++
A. insuavisACH-CF-476CF sputuma>256>256>256>256R++
A. insuavisACH-CF-777CF sputuma96>256>256>256R++
A. insuavisAXX-AEar swaba162562464R++
A. insuavisCIP-102062Blood122561624R++
A. marplatensisACH-ENV-4Lakea122562432R++
A. mucicolensACH-NCF-34Tracheal aspiratea1.561.51.5S
A. mucicolensACH-NCF-35Tracheal aspiratea2821.5S
A. mucicolensACH-NCF-36Blooda2622S
A. mucicolensACH-CF-510CF sputuma2822S
A. piechaudiiCIP-60.75TPharynx1.5633S
A. ruhlandiiCIP-77.26TSoil8241216R++
A. ruhlandiiAU19877CF sputum16>2564864R++
A. ruhlandiiAU19911CF sputum348612R++
A. ruhlandiiAU19929CF sputum>256>256>256>256R++
A. spaniusCIP-108199TBlood1.5644S
A. spaniusACH-NCF-37Foot wounda1411.5S
A. spaniusACH-CF-746CF sputuma2622S
A. xylosoxidansACH-CF-809CF sputuma128>256256>256R++
A. xylosoxidansACH-NCF-39Insertion-site skin swaba24>25664128R++
A. xylosoxidansACH-NCF-18Tracheal aspiratea64>256128256R++
A. xylosoxidansCIP-71.32TEar discharge192>256>256>256R++
A. xylosoxidansCIP-101902Pleural fluid>256>256>256>256R++
A. xylosoxidansCIP-102236Sputum48>256256>256R++
A. xylosoxidansACH-NCF-41Sputuma32>25664128R++
A. xylosoxidansACH-NCF-42Tracheal aspiratea82562464R++
A. xylosoxidansACH-ENV-1Dental instrumenta192>256>256>256R++
A. xylosoxidansACH-NCF-13Bronchial aspiratea64>256128>256R++
A. xylosoxidansACH-CF-805CF sputuma24>25648192R++
A. xylosoxidansACH-NCF-11Sputuma162563248R++
A. xylosoxidansACH-CF-842CF sputuma81922432R++
A. xylosoxidansACH-NCF-40Blooda32>25696192R++
A. xylosoxidansACH-ENV-5Rivera16>2562464R++
A. xylosoxidansACH-ENV-6Domestic hand-washing sinka32>25648128R++

AG, aminoglycoside; AMK, amikacin; CF, cystic fibrosis; GEN, gentamicin; MIC, minimum inhibitory concentration; NET, netilmicin; R, resistant.; S, susceptible; TOB, tobramycin.

Isolates collected in our laboratory.

The nrdA sequences analysis allowed identification of 48 of the 49 isolates. nrdA sequence of ACH-CF-583 harboured 39 nucleotide differences, with its closest match in database (genogroup 19) (Fig. 1) indicating that this isolate belonged to a novel genogroup or a novel species. Fourteen of the 49 studied isolates were categorized as AG-S. Interestingly, all isolates belonging to a same species harboured the same AG resistance pattern. In the resistant species, the level of resistance was sometimes variable among the isolates. Nevertheless, none of these isolates had been categorized as susceptible for all four AG molecules. A variable expression level of the efflux operon might account for these differences as already observed for Pseudomonas aeruginosa [16]. Distribution of the AG-S and AG-R isolates according to species identification is represented in a dendrogram (Fig. 2) generated from the nrdA sequences using the neighbour-joining method with 1000 bootstrap replications (MEGA6). We also included in the dendrogram the nrdA sequences of the type strains (LMG) of the recently described novel species. AG-S isolates were divided up into two clusters of species including A. animicus and A. mucicolens (cluster 1), and A. spanius and A. piechaudii (cluster 2). These two clusters were supported by high bootstrap values. All other isolates were AG-R and did not belong to cluster 1 or 2. They included the 16 A. xylosoxidans isolates and all isolates from the species A. aegrifaciens, A. denitrificans, A. dolens, A. genogroup 12, A. insolitus, A. insuavis, A. marplatensis and A. ruhlandii. A similar tree topology was obtained by using the maximum likelihood and the maximum parsimony methods (data not shown). There was a perfect correlation between the AG resistance profile and the presence of the AxyXY-OprZ efflux system. Indeed, the operon was detected in all AG-R isolates and not in the AG-S ones. An additional PCR was performed in all AG-S isolates with primers designed in flanking sequences of the axyXY-oprZ operon and confirmed the absence of the whole operon. Because the GC content of the efflux operon is similar to that of whole genome, we hypothesized that a deletion occurred in the course of evolution. These findings indicate that susceptibility or resistance to AG might be a phenotypic trait correlated with Achromobacter species evolution.
Fig. 1

ACH-CF-583 nrdA sequence alignment with its closest match (genogroup 19) in Achromobacter PubMLST database. Query: ACH-CF-583; Ref: closest match in database.

Fig. 2

Neighbour-joining dendrogram based on nrdA sequence. Numbers at nodes indicate bootstrap values. Scale bar indicates number of substitutions per site. AG-resistant (AG-R) isolates are in upper box; AG-susceptible (AG-S) isolates are in boxes ‘cluster 1’ and ‘cluster 2.’ AG resistance was not determined for the LMG strains.

To date, and to our knowledge, only four studies including an appropriate Achromobacter identification method report distribution of the different Achromobacter species in clinical samples. They indicate that A. xylosoxidans is the species the most frequently recovered from CF patients [11], [17], [18], [19]. Other species are also widely prevalent: A. ruhlandii, A. dolens and A. insuavis. It is noteworthy that all isolates belonging to these four species have been categorized as AG-R in the present work. One can therefore wonder whether these AG-R species are more pathogenic than the AG-S ones, which might explain their high prevalence. One might also hypothesize that these species have emerged under the selection pressure of AG treatment frequently prescribed to those in the CF population. In conclusion, AG resistance is the first phenotypic characteristic correlated with the different species of the genus Achromobacter. More studies including accurate species level identification are required in order to improve knowledge about the epidemiology and virulence of these pathogens. They might also help to elucidate whether the use of inhaled AG promotes selection of Achromobacter that belong to the species harbouring the AxyXY-OprZ efflux system.
  19 in total

1.  Achromobacter xylosoxidans n. sp. from human ear discharge.

Authors:  E Yabuuchi; A Oyama
Journal:  Jpn J Microbiol       Date:  1971-09

2.  Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.

Authors:  Julia Emerson; Sharon McNamara; Anne Marie Buccat; Kelly Worrell; Jane L Burns
Journal:  Pediatr Pulmonol       Date:  2010-04

3.  A multilocus sequence typing scheme implies population structure and reveals several putative novel Achromobacter species.

Authors:  Theodore Spilker; Peter Vandamme; John J Lipuma
Journal:  J Clin Microbiol       Date:  2012-07-11       Impact factor: 5.948

4.  Multilocus sequence analysis of isolates of Achromobacter from patients with cystic fibrosis reveals infecting species other than Achromobacter xylosoxidans.

Authors:  Winnie Ridderberg; Mikala Wang; Niels Nørskov-Lauritsen
Journal:  J Clin Microbiol       Date:  2012-06-06       Impact factor: 5.948

5.  Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain.

Authors:  Laura Barrado; Patricia Brañas; M Ángeles Orellana; M Teresa Martínez; Gloria García; Joaquín R Otero; Fernando Chaves
Journal:  J Clin Microbiol       Date:  2013-03-27       Impact factor: 5.948

6.  Achromobacter insolitus sp. nov. and Achromobacter spanius sp. nov., from human clinical samples.

Authors:  Tom Coenye; Marc Vancanneyt; Enevold Falsen; Jean Swings; Peter Vandamme
Journal:  Int J Syst Evol Microbiol       Date:  2003-11       Impact factor: 2.747

7.  Kerstersia gyiorum gen. nov., sp. nov., a novel Alcaligenes faecalis-like organism isolated from human clinical samples, and reclassification of Alcaligenes denitrificans Rüger and Tan 1983 as Achromobacter denitrificans comb. nov.

Authors:  Tom Coenye; Marc Vancanneyt; Margo C Cnockaert; Enevold Falsen; Jean Swings; Peter Vandamme
Journal:  Int J Syst Evol Microbiol       Date:  2003-11       Impact factor: 2.747

8.  Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  Christelle Vogne; Julio Ramos Aires; Christiane Bailly; Didier Hocquet; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis.

Authors:  M Wang; W Ridderberg; C R Hansen; N Høiby; S Jensen-Fangel; H V Olesen; M Skov; L E Lemming; T Pressler; H K Johansen; N Nørskov-Lauritsen
Journal:  J Cyst Fibros       Date:  2013-05-31       Impact factor: 5.482

10.  Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data.

Authors:  Lucie Amoureux; Julien Bador; Eliane Siebor; Nathalie Taillefumier; Annlyse Fanton; Catherine Neuwirth
Journal:  J Cyst Fibros       Date:  2012-09-01       Impact factor: 5.482

View more
  10 in total

1.  Role of AxyZ Transcriptional Regulator in Overproduction of AxyXY-OprZ Multidrug Efflux System in Achromobacter Species Mutants Selected by Tobramycin.

Authors:  Julien Bador; Catherine Neuwirth; Nadège Grangier; Marie Muniz; Leslie Germé; Jérémy Bonnet; Vignesh-Guru Pillay; Catherine Llanes; Claire de Curraize; Lucie Amoureux
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 2.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

3.  Longitudinal Surveillance and Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant Achromobacter Species from Cystic Fibrosis Patients.

Authors:  Ijeoma N Okoliegbe; Karolin Hijazi; Kim Cooper; Corinne Ironside; Ian M Gould
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 4.  Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging Pathogens Well-Armed for Life in the Cystic Fibrosis Patients' Lung.

Authors:  Quentin Menetrey; Pauline Sorlin; Estelle Jumas-Bilak; Raphaël Chiron; Chloé Dupont; Hélène Marchandin
Journal:  Genes (Basel)       Date:  2021-04-21       Impact factor: 4.096

5.  Achromobacter xylosoxidans is the predominant Achromobacter species isolated from diverse non-respiratory samples.

Authors:  L Amoureux; J Bador; T Verrier; H Mjahed; C DE Curraize; C Neuwirth
Journal:  Epidemiol Infect       Date:  2016-08-18       Impact factor: 4.434

6.  Uncovering Differences in Virulence Markers Associated with Achromobacter Species of CF and Non-CF Origin.

Authors:  Brankica Filipic; Milka Malesevic; Zorica Vasiljevic; Jovanka Lukic; Katarina Novovic; Milan Kojic; Branko Jovcic
Journal:  Front Cell Infect Microbiol       Date:  2017-05-29       Impact factor: 5.293

7.  A Pan-Genomic Approach to Understand the Basis of Host Adaptation in Achromobacter.

Authors:  Julie Jeukens; Luca Freschi; Antony T Vincent; Jean-Guillaume Emond-Rheault; Irena Kukavica-Ibrulj; Steve J Charette; Roger C Levesque
Journal:  Genome Biol Evol       Date:  2017-04-01       Impact factor: 3.416

8.  Proteomic identification of Axc, a novel beta-lactamase with carbapenemase activity in a meropenem-resistant clinical isolate of Achromobacter xylosoxidans.

Authors:  Frank Fleurbaaij; Alex A Henneman; Jeroen Corver; Cornelis W Knetsch; Wiep Klaas Smits; Sjoerd T Nauta; Martin Giera; Irina Dragan; Nitin Kumar; Trevor D Lawley; Aswin Verhoeven; Hans C van Leeuwen; Ed J Kuijper; Paul J Hensbergen
Journal:  Sci Rep       Date:  2018-05-25       Impact factor: 4.379

9.  Role of Efflux in Antibiotic Resistance of Achromobacter xylosoxidans and Achromobacter insuavis Isolates From Patients With Cystic Fibrosis.

Authors:  Hussein Chalhoub; Stefanie Kampmeier; Barbara C Kahl; Françoise Van Bambeke
Journal:  Front Microbiol       Date:  2022-03-28       Impact factor: 5.640

10.  First Documented Case of Percutaneous Endoscopic Gastrostomy (PEG) Tube-Associated Bacterial Peritonitis due to Achromobacter Species with Literature Review.

Authors:  Nishant Tripathi; Niki Koirala; Hirotaka Kato; Tushi Singh; Kishore Karri; Kshitij Thakur
Journal:  Case Rep Gastrointest Med       Date:  2020-01-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.